A Comprehensive Guide to CPT Code 84550 for Uric Acid Testing

In the vast and intricate world of medical coding, where thousands of Current Procedural Terminology (CPT) codes translate medical services into a universal language for billing and data analysis, a single five-digit number can tell a profound story. CPT code 84550: Uric acid; blood is one such code. On its surface, it appears simple—a straightforward code for a common blood test. But to view it merely as a line item on a claim is to miss its immense clinical, operational, and financial significance. This test is a critical diagnostic and monitoring tool for a spectrum of conditions that affect millions of patients worldwide, from the excruciatingly painful joints of gout to the silent progression of kidney disease and the high-stakes management of chemotherapy.

This article is designed to be the ultimate resource for understanding CPT code 84550. We will move beyond the basic definition and embark on a comprehensive journey. We will explore the physiology of uric acid, the clinical scenarios that necessitate testing, the technical nuances of the assay itself, and the complex rules that govern its appropriate billing and reimbursement. Whether you are a healthcare provider seeking to understand how to properly order and document for this test, a medical coder or biller aiming to ensure compliant and accurate claims submission, or a practice manager focused on the financial health of your organization, this deep dive into CPT 84550 will provide the exclusive, detailed knowledge you need to navigate this aspect of patient care with confidence and expertise.

2. The Clinical Significance of Uric Acid: Why We Test

Uric acid is the final breakdown product of purine metabolism in humans. Purines are natural substances found in all the body’s cells and in virtually all foods. They are essential building blocks for DNA and RNA. Under normal circumstances, the body maintains a careful balance between the production of uric acid (from the liver) and its elimination (primarily through the kidneys and, to a lesser extent, the intestines). Disruption of this balance, leading to elevated levels in the blood—a condition known as hyperuricemia—is the central theme behind the medical necessity for testing.

2.1. Gout: The King of Uric Acid Disorders

Gout is the most classic and well-known disorder associated with hyperuricemia. It is a form of inflammatory arthritis characterized by sudden, severe attacks of pain, redness, swelling, and tenderness in the joints, often at the base of the big toe. The pathophysiology is direct: when serum uric acid levels exceed their saturation point (generally above 6.8 mg/dL), monosodium urate crystals can form and deposit in joints and surrounding tissues. The body’s immune system recognizes these crystals as foreign invaders, triggering a massive inflammatory response that causes the intense pain of a gout attack.

While a high uric acid level is a major risk factor, not everyone with hyperuricemia develops gout, and not every gout attack occurs when levels are at their absolute peak. The role of CPT 84550 in gout is multi-faceted:

• Diagnosis: To support a clinical diagnosis of gout, especially when arthrocentesis (joint fluid analysis) is not performed or is inconclusive.

• Risk Assessment: To identify patients with hyperuricemia who are at risk for developing gout.

• Therapeutic Monitoring: To monitor the effectiveness of urate-lowering therapy (ULT) such as allopurinol or febuxostat. The goal of ULT is to reduce and maintain serum uric acid levels below 6.0 mg/dL (and often lower for those with tophi), preventing future attacks and allowing existing crystal deposits to dissolve.

2.2. Kidney Stones: The Crystalline Consequence

Uric acid is a common constituent of kidney stones (nephrolithiasis). Hyperuricemia can lead to the formation of pure uric acid stones or contribute to the development of calcium-based stones. Testing serum uric acid levels is a standard part of the metabolic workup for a patient who has formed a kidney stone. Identifying hyperuricemia allows for targeted preventive therapy, which may include dietary modifications, increased fluid intake, and medications like allopurinol or potassium citrate (which alkalinizes the urine, making uric acid more soluble).

2.3. Tumor Lysis Syndrome: An Oncologic Emergency

This is a critical, life-threatening condition that can occur after chemotherapy (or sometimes spontaneously) in patients with cancers that have a high tumor burden and rapid cell turnover, such as high-grade lymphomas and leukemias. The massive, rapid death of cancer cells releases enormous amounts of intracellular purines into the bloodstream, overwhelming the body’s ability to excrete them. This leads to severe hyperuricemia, which can cause acute kidney injury as uric acid crystals precipitate in the renal tubules. Monitoring serum uric acid (along with potassium, phosphate, and creatinine) is mandatory before and during chemotherapy in at-risk patients. Preventive measures like aggressive hydration and rasburicase (a drug that rapidly breaks down uric acid) are guided by these test results.

2.4. Chronic Kidney Disease: A Vicious Cycle

The relationship between uric acid and chronic kidney disease (CKD) is bidirectional. Impaired kidney function is a leading cause of secondary hyperuricemia because the kidneys cannot effectively excrete uric acid. Conversely, there is growing evidence that hyperuricemia itself may contribute to the progression of CKD through inflammatory pathways, endothelial dysfunction, and activation of the renin-angiotensin system. Therefore, monitoring uric acid levels is common in the management of patients with CKD.

3. CPT Code 84550: A Deep Dive into the Technical Specifications

3.1. Code Definition and Scope

CPT code 84550 is defined simply as “Uric acid; blood.” It is classified under the “Chemistry” subsection of the CPT Pathology and Laboratory section. This code is used to report the quantitative measurement of uric acid in a sample of whole blood, serum, or plasma. It is important to note that this code is unilateral; it is reported once per patient encounter regardless of how many times the blood is drawn or analyzed on the same day for the same purpose. It is not a timed code.

3.2. Methodology Matters: How the Test is Performed

Most modern clinical laboratories use automated analyzers and enzymatic methods to measure uric acid. The most common method involves the enzyme uricase (urate oxidase). The classic reaction is:

1. Uric acid + O₂ + H₂O —(Uricase)→ Allantoin + CO₂ + H₂O₂

2. The hydrogen peroxide (H₂O₂) produced then reacts with a chromogen in a reaction catalyzed by peroxidase (POD), producing a colored compound.

3. The intensity of the color produced is directly proportional to the concentration of uric acid in the sample and is measured by a spectrophotometer.

This uricase method is highly specific for uric acid and is considered the gold standard. Older chemical methods (e.g., phosphotungstic acid reduction) are non-specific and can be interfered with by other substances in the blood like glucose and glutathione; they are now largely obsolete.

3.3. Units of Measurement and Reference Ranges

Uric acid levels are most commonly reported in milligrams per deciliter (mg/dL) in the United States. The International System of Units (SI) unit is micromoles per liter (µmol/L). The conversion factor is: 1 mg/dL = 59.48 µmol/L.

Reference ranges can vary slightly between laboratories based on the specific assay and patient population. However, general guidelines are:

Table 1: Typical Reference Ranges for Serum Uric Acid. Always consult your specific laboratory’s report.

Factors such as age, sex, diet (high purine intake), alcohol consumption, obesity, and renal function all influence an individual’s baseline uric acid level.

4. The Coding Ecosystem: Placement, Modifiers, and Bundling

Correctly reporting 84550 involves more than just appending the code to a claim. It requires an understanding of the context in which it is performed.

4.1. Place of Service (POS) and Its Impact

Where the test is performed dictates how it is billed.

• POS 21: Inpatient Hospital: The test is typically bundled into the DRG (Diagnosis-Related Group) payment for the inpatient stay. It is not separately billed to Medicare Part B. The hospital’s lab charges are part of the facility’s cost.

• POS 22: Outpatient Hospital/ASC: Billed by the hospital on the UB-04 claim form. Reimbursement is often based on the Hospital Outpatient Prospective Payment System (OPPS) or a negotiated rate with payers.

• POS 11: Physician Office: If the practice has an in-office Clinical Laboratory Improvement Amendments (CLIA)-waived device that performs uric acid testing, they can bill 84550 on the CMS-1500 form. Reimbursement is typically based on the Medicare Physician Fee Schedule (MPFS) or a contracted rate.

• Reference Laboratory: If a provider’s office draws the blood and sends it to an external lab (e.g., Quest, Labcorp), the reference lab bills for the technical component (TC) using 84550. The ordering provider does not bill for the test.

4.2. Modifier Use with 84550 (e.g., -91, -59)

Modifier use with 84550 is generally rare but important in specific scenarios.

• Modifier -91: Repeat Clinical Diagnostic Laboratory Test: This modifier is used if the same test is repeated on the same day for a different clinical reason. For example, a patient on chemotherapy has a baseline uric acid level in the morning (84550). After a dose of rasburicase, a repeat test is run in the afternoon to confirm the level has dropped. The second test could be billed as 84550-91. It is crucial to have documentation supporting the medical necessity of the repeat test on the same day. Payer policies on modifier -91 can be strict.

• Modifier -59: Distinct Procedural Service: This is rarely appropriate for a single lab test like 84550. Its use would be considered only in highly unusual circumstances where the test is performed on two distinctly separate specimens for two wholly unrelated reasons, and no other modifier applies. Its misuse is a major audit target.

4.3. Understanding NCCI Edits and CCI

The National Correct Coding Initiative (NCCI or CCI) edits are pairs of CPT codes that generally should not be billed together by the same provider for the same patient on the same day. NCCI edits exist to prevent unbundling. Code 84550 has many NCCI edits with comprehensive metabolic panels (CMP, 80053) and basic metabolic panels (BMP, 80048). Since a CMP includes a uric acid measurement, billing 84550 and 80053 together would be incorrect. The CMP is billed, and 84550 is bundled into it. If uric acid is measured separately from a panel, it must be justified by a different clinical circumstance and may require a modifier (like -59) if the NCCI edit allows it. However, the correct action is almost always to bill only the panel or the individual test, not both.

5. The Financial Landscape: Reimbursement and Payer Policies

Reimbursement for 84550 is not a fixed number; it varies significantly by payer, geographic location, and setting.

5.1. Medicare and the Clinical Laboratory Fee Schedule (CLFS)

For most community-based testing (e.g., doctor’s office sending to a reference lab, independent lab), Medicare reimbursement for 84550 is determined by the Clinical Laboratory Fee Schedule (CLFS). The CLFS is a national fee schedule with geographic adjustments. The payment rate is calculated based on the weighted median of private payer rates from a previous data reporting period, as mandated by the PAMA (Protecting Access to Medicare Act) of 2014.

As of the 2025 CLFS (for illustrative purposes; always check current year data), the national limitation amount for 84550 is approximately $6.00 – $9.00. This is the base rate, and it will be adjusted by a geographic practice cost index (GPCI). Medicare pays 100% of the approved CLFS amount for medically necessary tests; there is no coinsurance or deductible for patients for CLFS services.

5.2. Navigating Commercial Payer Policies

Commercial payers (e.g., Blue Cross Blue Shield, Aetna, UnitedHealthcare) establish their own negotiated rates for 84550. These rates are part of the contract between the insurance company and the laboratory or provider organization. They can be higher or lower than the Medicare rate. It is imperative for labs and billers to be familiar with their specific contracts.

More importantly, commercial payers have their own medical necessity policies and frequency limits. For example, a payer may limit uric acid testing for stable gout on medication to twice a year. Testing more frequently without a documented clinical reason (like a flare or medication titration) will likely lead to a denial. Always verify coverage and prior authorization requirements for non-acute situations.

5.3. The Role of Medical Necessity and Documentation

The linchpin of reimbursement is medical necessity. The diagnosis code(s) reported on the claim must justify the reason for the test. Without a covered, appropriate diagnosis code, the claim will be denied, regardless of how correctly the CPT code was reported.

Examples of Supporting ICD-10-CM Codes for 84550:

• M10.9 – Gout, unspecified

• M10.0 – Idiopathic gout

• M10.3 – Gout due to renal impairment

• E79.0 – Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

• N20.0 – Calculus of kidney (for stone formers)

• C81-C96 – Various codes for malignant neoplasms (for tumor lysis monitoring)

• N18.9 – Chronic kidney disease, unspecified

The provider’s documentation in the medical record must clearly state the reason for the test: “Patient presents with acute, painful swelling of the first MTP joint, suspect gout, order uric acid level.” This documentation must align with the diagnosis code chosen.

6. Ordering the Test: A Guide for Providers

6.1. Crafting a Medically Necessary Narrative

Providers play the most critical role in ensuring the test is paid for. The order itself should tell a story. Instead of just checking a box on a lab requisition, a brief note can make a significant difference: “Order uric acid to monitor response to allopurinol started 3 months ago for chronic tophaceous gout (M10.9). Goal is <6.0 mg/dL.” This directly links the test to a specific condition and treatment plan.

6.2. Frequency of Testing: How Often is Justified?

There is no universal rule, but clinical guidelines provide direction:

• Initial Diagnosis: A baseline test is needed.

• Initiating ULT: Levels are often checked at 2-4 week intervals initially to titrate the medication dose until the target level is achieved.

• Stable on ULT: Once the target uric acid level is stable, monitoring can often be extended to every 6-12 months.

• Acute Flare: A test during a flare is common, though levels can be paradoxically normal.

• Tumor Lysis Risk: Can be multiple times per day during high-risk chemotherapy.

Ordering tests at a frequency that exceeds accepted clinical guidelines without a documented reason is a common cause of audit flags and denials.

7. Beyond Serum: Other Uric Acid Tests and Their Codes

While 84550 is for blood, uric acid can be measured in other specimens.

7.1. Urinary Uric Acid (CPT Code 84560)

CPT 84560: Uric acid; other source is typically used for a 24-hour urine collection to measure total urinary uric acid excretion. This is crucial for classifying the type of hyperuricemia:

• Underexcretion: accounts for ~90% of cases; normal or low urinary uric acid.

• Overproduction: high urinary uric acid excretion.
  This distinction can guide treatment, as uricosuric drugs (like probenecid) that increase renal excretion are only effective in underexcreters and are contraindicated in overproducers (as they could cause kidney stones).

7.2. Synovial Fluid Analysis for Crystals (CPT Code 89060)

The definitive diagnosis of gout is made by identifying monosodium urate crystals in synovial fluid aspirated from an affected joint. This is reported with CPT 89060: Crystal identification by light microscopy with polarization, any body fluid (except urine). This is a different procedure from a chemical measurement and has its own code and higher reimbursement.

8. Case Studies: Real-World Application of CPT 84550

8.1. Case Study 1: The Acute Gout Flare

• Scenario: A 55-year-old male presents to his PCP with 24 hours of severe, throbbing pain and redness in his right big toe. He has a history of hypertension but no prior gout diagnoses.

• Action: The PCP examines him, suspects gout, and orders a serum uric acid test (84550). The result comes back at 9.8 mg/dL.

• Coding & Billing: The coder bills 84550 with diagnosis code M10.9 (Gout, unspecified). The medical record documents the acute symptoms and physical exam findings. The test is medically necessary and likely reimbursed.

• Outcome: The elevated level supports the diagnosis. The provider prescribes an NSAID and colchicine for the acute flare and schedules a follow-up to discuss long-term ULT.

8.2. Case Study 2: Monitoring Allopurinol Therapy

• Scenario: A 62-year-old female with a established history of gout has been on allopurinol 300mg daily for the past 4 months. She is seen for a routine follow-up and is asymptomatic.

• Action: As part of her monitoring, the provider orders a uric acid level (84550). The result is 5.2 mg/dL.

• Coding & Billing: The coder bills 84550 with diagnosis code M10.9 (Gout, unspecified). The note states “monitoring uric acid level on allopurinol therapy.” This demonstrates ongoing management of a chronic condition.

• Outcome: The level is at goal (<6.0 mg/dL). The provider continues the current dose and recommends testing again in 6 months.

8.3. Case Study 3: Pre-Chemotherapy Baseline

• Scenario: A 48-year-old male is about to initiate chemotherapy for Burkitt lymphoma, a high-risk tumor for TLS.

• Action: The oncologist orders a baseline metabolic panel, which includes LDH, potassium, phosphate, creatinine, and a separate uric acid test (84550) before the first cycle.

• Coding & Billing: The coder bills 80048 (BMP) and 84550. Because the BMP does not include uric acid, there is no NCCI edit bundling them. The diagnosis code is C83.7 (Burkitt lymphoma).

• Outcome: The baseline uric acid is slightly elevated at 8.0 mg/dL. This places the patient at higher risk, prompting the use of aggressive prophylactic hydration and rasburicase.

9. Compliance and Audits: Avoiding Red Flags

Consistently misusing CPT 84550 can attract unwanted attention from auditors. Common red flags include:

• Routine Ordering: Ordering a uric acid on every patient without a specific indication.

• Frequency Mismatch: Testing stable patients every month for years without a change in management.

• Unbundling: Billing 84550 with a CMP (80053) for the same patient on the same day without a valid, documented reason that justifies a separate specimen and a modifier (which is rarely appropriate).

• Lack of Medical Necessity: Using a non-covered diagnosis code (e.g., R79.89 – Other specified abnormal findings of blood chemistry) when a covered code like M10.9 is more accurate.

The best defense is a proactive offense: strong provider documentation, knowledgeable coding, and internal audits to ensure patterns of use align with clinical guidelines and payer policies.

10. The Future of Uric Acid Testing: Emerging Trends

The field is not static. Several trends are emerging:

• Point-of-Care Testing (POCT): The development of CLIA-waived, handheld devices that can provide a uric acid result from a fingerstick in minutes is growing. This allows for immediate titration of medication in the clinic. The same code, 84550, is used for POCT.

• Expanded Role in Health Conditions: Research continues into the potential role of uric acid in hypertension, metabolic syndrome, and cardiovascular disease, which may broaden the appropriate indications for testing in the future.

• Automated Prior Authorization: As AI and automation become integrated into EHRs, systems may soon automatically check payer policies for medical necessity and even submit prior authorization requests for tests like 84550 when a provider orders them, streamlining the administrative process.

11. Conclusion

CPT code 84550, “Uric acid; blood,” is a deceptively simple entry in the coding lexicon that sits at the intersection of clinical medicine, laboratory science, and healthcare economics. Its appropriate use requires a deep understanding of the pathophysiology of hyperuricemia, the technical aspects of the assay, and the complex rules of medical coding and reimbursement. By ensuring that test ordering is driven by documented medical necessity, that coding is precise and compliant, and that billing practices are aligned with payer policies, healthcare organizations can ensure that this fundamental diagnostic tool remains accessible to patients while safeguarding their own financial and regulatory integrity. Mastering the details of 84550 is a perfect example of how expertise in the nuances of medical coding directly supports high-quality, sustainable patient care.

12. Frequently Asked Questions (FAQs)

Q1: Can I bill CPT 84550 if I use a point-of-care device in my office?
A: Yes, provided your office has a valid CLIA Certificate of Waiver for the specific device and you perform the test in compliance with CLIA regulations. You bill 84550 on your CMS-1500 claim form.

Q2: A patient had a Comprehensive Metabolic Panel (CMP) and a separate uric acid test drawn at the same time. Can I bill both 80053 and 84550?
A: Generally, no. The CMP includes a uric acid measurement. Billing both is considered unbundling. You should only bill the CMP (80053). The separate uric acid test would only be justified if it was performed on a different specimen for a different clinical reason at a different time, which is an extremely rare scenario.

Q3: Medicare denied my claim for 84550 as “not medically necessary.” What should I do?
A: First, check the diagnosis code you used. It must be a covered diagnosis per the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCDs). Codes like E79.0 (Hyperuricemia) or M10.9 (Gout) are typically covered. If the code is correct, you may need to appeal the denial with a copy of the patient’s medical records that document the reason for the test (e.g., note describing gout symptoms).

Q4: How often is it appropriate to test uric acid levels for a patient with gout?
A: Frequency should be based on clinical status. When first starting medication, testing every 2-4 weeks is common to titrate the dose. Once the patient is stable and at their target uric acid level (usually below 6.0 mg/dL), testing every 6-12 months is typically sufficient. Testing during acute flares is also common. Frequent testing without a change in management or clinical status may be denied by payers.

Q5: What is the difference between CPT 84550 and CPT 84560?
A: CPT 84550 is for measuring uric acid in a blood sample (serum or plasma). CPT 84560 is for measuring uric acid in “other sources,” which almost always means a 24-hour urine collection. The urine test helps determine if a patient is overproducing or underexcreting uric acid, which can influence treatment choices.

13. Additional Resources

• AMA CPT® Professional Edition: The definitive source for CPT code descriptions, guidelines, and parenthetical notes. Must be updated annually.

• CMS.gov: For Medicare-specific information, including the Clinical Laboratory Fee Schedule (CLFS), National Coverage Determinations (NCDs), and manuals.

• Novitas Solutions, First Coast Service Options, etc.: Medicare Administrative Contractors (MACs) publish Local Coverage Determinations (LCDs) and articles that provide detailed guidance on medical necessity for tests like 84550 in their regions.

• American College of Rheumatology (ACR): Provides clinical guidelines for the management of gout, including recommendations on laboratory monitoring.

• Clinical Laboratory Improvement Amendments (CLIA): CMS CLIA website for regulations on laboratory testing.

• National Correct Coding Initiative (NCCI) Policy Manual: Contains specific chapters on Pathology and Laboratory services explaining bundling edits.

 

 

 

Date: September 2, 2025
Author: The Health Economics & Coding Strategist
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice, legal advice, or a definitive guide for medical coding. Medical coding is complex and subject to change. Always consult the most current AMA CPT® manual, payer-specific policies, and certified professional coders for accurate, individualized coding and billing guidance.